Eledon Pharmaceuticals Inc Stock Price, News & Analysis

Eledon Pharmaceuticals plans to release its financial results for the fourth quarter and full year ended December 31, 2022, on March 30, 2023, following the close of trading. A conference call and webcast will be hosted at 4:30 p.m. ET on the same day. Investors can join via toll-free and international numbers or access the webcast link provided in the announcement. Eledon, a clinical-stage biotechnology company headquartered in Irvine, California, focuses on developing treatments targeting the CD40 Ligand pathway, with its lead compound being tegoprubart, an anti-CD40L antibody.

Eledon Pharmaceuticals announced plans to present two posters at the World Congress of Nephrology 2023 in Bangkok, Thailand, from March 30 – April 2, 2023. The presentations will detail safety and efficacy data from ongoing trials of tegoprubart, an anti-CD40L antibody, focused on kidney transplantation and IgA Nephropathy (IgAN). The first presentation, highlighting data on preventing rejection in kidney transplants, is scheduled for March 31, while the second, detailing findings on IgAN, will take place on April 1. Both posters will be available on the company’s investor website post-event.

Eledon Pharmaceuticals, Inc. announced that CEO David-Alexandre C. Gros will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET. Interested participants can register for the presentation webcast here. A replay will be available on the company’s website after the live session. Eledon is developing innovative therapies targeting the CD40 Ligand pathway, including its lead compound, tegoprubart, for organ and cell transplants, autoimmune diseases, and ALS.

Eledon Pharmaceuticals is focusing resources on advancing tegoprubart for kidney transplantation, with ongoing enrollment in a Phase 1b trial and plans for a Phase 2 BESTOW trial set to begin in mid-2023. The company deprioritized its IgA Nephropathy program and discontinued its islet cell transplantation efforts to concentrate on kidney transplant opportunities. Eledon has sufficient financial resources to support its operations into 2024. Initial data from the ongoing trials are expected to be released at the World Congress of Nephrology in March 2023.

Eledon Pharmaceuticals announced on December 20, 2022, that the Critical Path Institute's Transplant Therapeutic Consortium received EMA qualification for the iBox Scoring System as a secondary efficacy endpoint in kidney transplant trials. This novel endpoint aims to enhance immunosuppressive therapy (IST) applications, predicting graft failure using various biomarkers, including renal function measures and immunologic responses. CEO David Alexandre C. Gros expressed commitment to integrating the iBox system into future trials for tegoprubart, their lead drug targeting allograft rejection.

Eledon Pharmaceuticals reported significant advancements in its clinical trials and regulatory approvals for tegoprubart, aimed at preventing organ rejection in kidney transplant patients and treating IgA Nephropathy (IgAN). The FDA cleared IND applications for both indications, allowing for Phase 2 trials to commence. The company has dosed initial patients in an ex-U.S. Phase 1b trial and plans to expand globally, including China in 2023. Despite a net loss of $10.5 million in Q3 2022, Eledon maintains adequate financial resources with $65.9 million in cash, enough to sustain operations into 2024.

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its third-quarter financial results for the period ended September 30, 2022, on November 14, 2022, after market close. A conference call and webcast to discuss these results will take place at 4:30 PM ET on the same day. Eledon focuses on developing treatments targeting the CD40L pathway, with its lead candidate being tegoprubart, intended for organ transplant recipients, autoimmune disease patients, and those with ALS. The event will be archived on the company's website for one year.

Eledon Pharmaceuticals (NASDAQ: ELDN) announces its participation in two significant medical conferences this November. At the American Society of Nephrology's Kidney Week 2022 (November 3-6 in Orlando, FL), Eledon will present two posters focusing on the safety and efficacy of tegoprubart in treating IgA nephropathy and its potential for ALS. Additionally, a poster on tegoprubart's safety profile in ALS will be showcased at the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) conference (November 1-3 in Clearwater Beach, FL). Eledon specializes in treatments for autoimmune diseases and organ transplant needs.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced participation in two upcoming conferences. On October 6, Steven Perrin, Ph.D., will engage in a panel discussion on ALS treatment at the Cantor Neurology & Psychiatry Conference. On October 7, Jeff Bornstein, M.D., will present on the safety and efficacy of tegoprubart for ALS patients at the ALS One 5th Annual ALS Research Symposium. Both presentations are exclusive to registered attendees. Eledon focuses on developing therapies targeting the CD40L pathway for organ transplant, autoimmune diseases, and ALS.